$RKDA

Arcadia Biosciences, Inc.

Arcadia Biosciences sells Zola coconut water to consumers through grocery retailers and foodservice distributors across the United States. Sourced, grown, harvested and packaged in Thailand, Zola is available in original, original with pulp, espresso and pineapple flavors. Arcadia makes money from selling these beverage products. The company previously commercialized wheat-based food products and earned income from trait licensing and royalty agreements, but it no longer retains effective commercialization rights to its wheat patents and does not expect future license or royalty fees from wheat intellectual property. Arcadia’s corporate headquarters are in Dallas, Texas. As of December 31, 2025, it had eight employees.

No enriched coverage for $RKDA in the last 7 days.

No SEC Form 4 filings for $RKDA in the last 30 days.

See all $RKDA insider activity →
Med

Arcadia Biosciences 3Q 2026: Revenue $1.62M, EPS $0.29 — 10-Q Summary

Arcadia Biosciences reported 3Q 2026 revenue of $1.62M, up 24% YoY, and net income of $1.76M, up 105% YoY. EPS was $0.29, down 53.2% YoY. The company cited strong product volumes and a $2.6M gain from warrant and option liabilities. Costs fell 14% due to a $175K tariff refund. Arcadia expressed doubt about its ability to continue as a going concern.

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

Arcadia Biosciences, Inc. (RKDA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Omnibus Equity Incentive Plan As further described in Item 5.07 below, the stockholders of Arcadia Biosciences, Inc. (

RKDA sentiment & insider activity

Recent RKDA coverage spans corporate actions, earnings and financial news.

What's driving RKDA

  • Earnings miss and cash‑flow doubts likely pressure the stock.

    tradingview.com · Nov 12, 2026

  • Earnings beat and profit swing suggest upside pressure.

    SEC EDGAR 8-K · Nov 12, 2026

  • Approval of a new equity incentive plan may dilute existing shares but could align management incentives; reverse split authority may affect share price perception.

    SEC EDGAR 8-K · Sep 15, 2026

  • The filing highlights continued losses and a balance-sheet shift tied to PIPE financing, which can drive near-term liquidity and dilution risk pricing.

    SEC EDGAR 8-K · Aug 13, 2026

  • Potential dilution from Series A-1 option exercise and a discretionary reverse split are both shareholder votes that can materially change per-share price, float, and compliance risk.

    stocktitan.net · Jul 31, 2026

AlphAI scores every news story that mentions RKDA with an AI model for sentiment and relevance, and aggregates insider trades from Arcadia Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RKDA

Score
$RKDAMedEarnings

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

$RKDALowShareholder vote

Arcadia Biosciences, Inc. (RKDA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Omnibus Equity Incentive Plan As further described in Item 5.07 below, the stockholders of Arcadia Biosciences, Inc. (

$RKDAMedEarnings

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

Arcadia Biosciences (NASDAQ: RKDA) plans share issuance and reverse stock split vote

Arcadia Biosciences (RKDA) will hold a virtual annual meeting on Sept. 10, 2026 to vote on eight proposals. Shareholders will consider issuing up to 3,993,296 common shares from Series A-1 Preferred Investment Options tied to a June 12, 2026 private placement, and authorizing a reverse split of 1-for-2 to 1-for-10 to regain Nasdaq’s $1 minimum bid compliance.

Arcadia Biosciences, Inc. (RKDA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001469443 false 0001469443 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01,

$RKDAMedOffering· $4M · proposed

Arcadia Biosciences, Inc. (RKDA): Entry into a Material Definitive Agreement

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 rkda-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 11, 2026 between Arcadia Biosciences, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

Arcadia Biosciences (NASDAQ: RKDA) details 2025 board, compensation and option deal

Arcadia Biosciences filed an amendment to its 2025 annual report, detailing board and committee structure, executive and non-employee director compensation (including option grants), and related-party transactions, without updating previous financial results. Key figures include CEO Thomas J. Schaefer's 2025 total compensation of $300,001 and audit fees of $892,001. The report also highlights a January 2026 inducement transaction where major holders exercised preferred investment options for approximately $2.1 million in cash and received new preferred investment options.

Related tickers